Genesis Biotechnology Group Announces Partnership with Yale University

Collaboration aims to accelerate the development and translation of Yale’s research and innovation projects to a decision point

HAMILTON, N.J., – Genesis Biotechnology Group® (GBG) and its CRO arm Genesis Drug Discovery & Development™ (GD3) announced today that it has entered into a partnership with Yale University to offer an integrated portfolio of drug discovery services from “target validation” to “lead optimization” to the awardees of the Blavatnik Fund for Innovation. The partnership is a part of GD3’s efforts to offer early drug discovery-based services to Yale’s researchers, allowing their breakthrough research to get to the market as new drugs and treatments.

Read More…